MYD88 and neuropathic pain: Consistently, upregulation of TLR4 during the development of DNP in the spinal cord has been identified, and several drugs including coenzyme Q10 and duloxetine contribute to TLR4/Myd88/NF-κB signaling pathway inhibition in the occurrence of neuropathic pain [14, 43, 44].